argenx 2030 vision announced; PC-POTS discontinued
argenx unveiled its 2030 vision “Taking Breakthrough Science to 50,000 Patients” to be presented in-depth during its upcoming R&D Day on July 16. The presentation will include topline Phase 2 data for efgar in Sjogren's disease and for empa in MMN, as well as additional detail on studies in myositis, DGF, DM, new indications and a next wave of clinical candidates. Development in PC-POTS has also been discontinued as Phase 2 data revealed no improvement vs. placebo. We scrap PC-POTS from our SOTP, now landing at a TP of € 420 (previously € 435), while we reiterate a Buy rating and look forward to the expected FDA decision on CIDP by June 21.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.